WO2013165898A3 - Compositions and methods for inhibiting resolvases - Google Patents

Compositions and methods for inhibiting resolvases Download PDF

Info

Publication number
WO2013165898A3
WO2013165898A3 PCT/US2013/038650 US2013038650W WO2013165898A3 WO 2013165898 A3 WO2013165898 A3 WO 2013165898A3 US 2013038650 W US2013038650 W US 2013038650W WO 2013165898 A3 WO2013165898 A3 WO 2013165898A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
resolvases
inhibiting
methods
inhibitors
Prior art date
Application number
PCT/US2013/038650
Other languages
French (fr)
Other versions
WO2013165898A2 (en
Inventor
Frederic D. Bushman
Young Hwang
Matt CULYBA
Original Assignee
The Trustees Of The University Of Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of The University Of Pennsylvania filed Critical The Trustees Of The University Of Pennsylvania
Priority to US14/397,994 priority Critical patent/US20150094327A1/en
Publication of WO2013165898A2 publication Critical patent/WO2013165898A2/en
Publication of WO2013165898A3 publication Critical patent/WO2013165898A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/065—Poxviridae, e.g. avipoxvirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention provides a fluorescence polarization (FP)-based assay to identify inhibitors of resolvase-DNA cleavage. The invention also provides resolvase inhibitors identified by the assay, as well as derivatives and analogs of the inhibitors. The compositions of the invention may be used to treat a poxvirus infection.
PCT/US2013/038650 2012-05-01 2013-04-29 Compositions and methods for inhibiting resolvases WO2013165898A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/397,994 US20150094327A1 (en) 2012-05-01 2013-04-29 Compositions and methods for inhibiting resolvases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261640928P 2012-05-01 2012-05-01
US61/640,928 2012-05-01

Publications (2)

Publication Number Publication Date
WO2013165898A2 WO2013165898A2 (en) 2013-11-07
WO2013165898A3 true WO2013165898A3 (en) 2014-01-16

Family

ID=49515015

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/038650 WO2013165898A2 (en) 2012-05-01 2013-04-29 Compositions and methods for inhibiting resolvases

Country Status (1)

Country Link
WO (1) WO2013165898A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210106506A (en) 2018-12-21 2021-08-30 셀진 코포레이션 Thienopyridine inhibitor of RIPK2
EP4146345A2 (en) 2020-05-05 2023-03-15 Teon Therapeutics, Inc. Cannabinoid receptor type 2 (cb2) modulators and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071862A2 (en) * 2004-12-30 2006-07-06 Takeda Pharmaceutical Company Limited Polymorphs of 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate
WO2009008906A2 (en) * 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses
US20100056516A1 (en) * 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006071862A2 (en) * 2004-12-30 2006-07-06 Takeda Pharmaceutical Company Limited Polymorphs of 1-(2-methylpropyl)-1h-imidazo[4,5-c][1,5]naphthyridin-4-amine ethanesulfonate
US20100056516A1 (en) * 2006-07-17 2010-03-04 Williams Peter D 1-hydroxy naphthyridine compounds as anti-hiv agents
WO2009008906A2 (en) * 2007-02-06 2009-01-15 The Trustees Of The University Of Pennsylvania Therapeutic compounds for blocking dna synthesis of pox viruses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CULYBA, M ET AL.: "Bulged DNA Substrates For Identifying Poxvirus Resolvase Inhibitors.", NUCLEIC ACIDS RESEARCH, vol. 40, no. 16, 11 May 2012 (2012-05-11), pages E124, Retrieved from the Internet <URL:http://www.ncbi.nlm.nih.gov/pmc/articleslPMC34398751pdf/gks325.pdf> [retrieved on 20131030] *

Also Published As

Publication number Publication date
WO2013165898A2 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
AU2018236800B2 (en) DNA-PK inhibitors
WO2013163190A8 (en) Dna-pk inhibitors
TN2013000348A1 (en) Compounds and compositions as trk inhibitors
WO2014028589A3 (en) 4-HETEROARYL SUBSTITUTED BENZOIC ACID COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MD20140136A2 (en) Inhibitors of hepatitis C virus
WO2014153100A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2014153235A3 (en) Arginine methyltransferase inhibitors and uses thereof
GEP201706695B (en) Substituted 4-phenyl-pyridi-nes for the treatment of nk-1 receptor related diseases
EP4219465A3 (en) Prmt5 inhibitors and uses thereof
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
MX2015005015A (en) Heteroaryl inhibitors of pde4.
WO2011153157A3 (en) Benzoquinolone inhibitors of vmat2
EA201590224A1 (en) IMIDAZOTRIASINCARBONITRILE USED AS KINASE INHIBITORS
WO2013003298A3 (en) Inhibitors of pde10
PH12015500211A1 (en) 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
BR112014028991A2 (en) triazoles as kv3 inhibitors
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
PH12016501462A1 (en) Neprilysin inhibitors
WO2013057013A3 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MX2015000980A (en) Aryl lactam kinase inhibitors.
UA117032C2 (en) A selective inhibitor of phosphatidylinositol 3-kinase-gamma
MX2014001604A (en) Anthranilamide compounds and their use as pesticides.
AU2015292632B2 (en) Aldosterone synthase inhibitors
WO2016164295A3 (en) Fused pyridines as adaptor associated kinase 1 (aak1) inhibitors
WO2012154879A3 (en) Autophagy inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13784316

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 14397994

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 13784316

Country of ref document: EP

Kind code of ref document: A2